InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.

Original reporting
Published Aug 20, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate — source image
Decision brief

The 30-second read

$NSPRBearishMed
01

Why it matters

The earnings miss and recall charge increase short‑term risk, but the modest EPS beat and announced $9 M annual cost‑saving plan provide a slight upside cushion.

02

Market read

Earnings release is the primary catalyst for NSPR; no broader macro or sector move.

03

What to watch

Potential FDA decisions later in 2026 could materially improve outlook if approvals are granted.

Relevance 7/10Novelty 8/10Timing: post‑earnings release

Background

InspireMD (Nasdaq: NSPR) is a micro‑cap medical‑device company focused on carotid artery stents, currently facing a voluntary recall of its CGuard Prime 135 cm system.

Company-level read

Ticker impact

$NSPRBearishMedium confidence
Context

InspireMD reported Q2 2026 results with revenue miss and a narrow loss per share beat, plus a recall impact and cost‑saving actions.

Expected impact

Potential further short pressure; price may test lower support around $0.85‑$0.90.

Evidence & confidence

Revenue fell short of estimates and a $734k recall charge hurt margins, while EPS beat is modest and no guidance was given.

Market effects

Highlights ongoing regulatory and recall risks for carotid‑stent manufacturers.

US‑focused recall may weigh on other US med‑device stocks.

Limited; primarily affects micro‑cap investors and niche med‑device sector.

Counterpoint

Cost‑saving actions and a loss‑per‑share beat could support a bounce if cash runway remains sufficient.

Key entities

  • Marvin Slosman

    CEO of InspireMD, discussed regulatory progress and cost‑saving measures.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR